Alembic Pharmaceuticals Ltd (APLLTD) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company reported a strong start to the fiscal year with a 26% year-on-year growth in consolidated revenue, driven by broad-based growth across all major business segments.
- The US generics business was a standout performer, growing 49% YoY, primarily driven by increased volumes, new product launches like Bosutinib, and better utilization of manufacturing assets.
- Profitability showed resilience despite strategic investments in R&D and the US branded platform, with EBITDA growing 21% YoY to INR 348 crores.
- The company has upgraded its full-year revenue growth guidance from a low double-digit range to closer to the mid-teen range, citing strong Q1 performance and positive momentum in the US market.
- Strategic priorities remain focused on building a robust chronic portfolio in India, expanding the US generics pipeline with complex products, and scaling the new US branded specialty business.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.